SCHEMBL576427

SCHEMBL576427

O=S(=O)(OS(=O)(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.55
ALDH1A1 P00352 6/20 0.50
TDP1 Q9NUW8 3/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
PARL Q9H300 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CA12 O43570 1/20 0.50
CA3 P07451 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
CA5A P35218 1/20 0.50
CA7 P43166 1/20 0.50
PLA2G7 Q13093 1/20 0.50
CA9 Q16790 1/20 0.50
CA13 Q8N1Q1 1/20 0.50
CA14 Q9ULX7 1/20 0.50
CA5B Q9Y2D0 1/20 0.50
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31452871 1.00 HTR6 (0.55) HTR6ALDH1A1TDP1CA1CA2
SCHEMBL31452872 1.00 HTR6 (0.55) HTR6ALDH1A1TDP1CA1CA2
Magnesium SCHEMBL30610988 0.97 HTR6 (0.52) HTR6ALDH1A1TDP1CA1CA2
Potassium SCHEMBL29613228 0.97 HTR6 (0.52) HTR6ALDH1A1TDP1CA1CA2
SCHEMBL31452875 0.97 HTR6 (0.52) HTR6ALDH1A1TDP1CA1CA2
SCHEMBL29121435 0.97 HTR6 (0.52) HTR6ALDH1A1TDP1CA1CA2
Calcium SCHEMBL31452873 0.97 HTR6 (0.52) HTR6ALDH1A1TDP1CA1CA2
Ammonia Solution, Strong SCHEMBL31603815 0.97 HTR6 (0.52) HTR6ALDH1A1TDP1CA1CA2
SCHEMBL28345961 0.95 HTR6 (0.50) HTR6ALDH1A1TDP1CA1CA2
Sulfuric Acid SCHEMBL25411375 0.90 HTR6 (0.46) HTR6ALDH1A1TDP1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117865932-B Preparation method of benzothiophene sulfone compound with medicinal and fluorescent activity BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY (CN) 2026-05-26 CN claimed
WO-2026100731-A1 COMPOSITION FOR OPTICAL MATERIAL, POLYMERIZABLE COMPOSITION FOR OPTICAL MATERIAL, OPTICAL MATERIAL, AND LENS 三井化学株式会社 2026-05-15 WO claimed
US-12540140-B2 Process for the preparation of remimazolam FRESENIUS KABI ONCOLOGY LTD. (IN) 2026-02-03 US claimed
US-20250263414-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF REMIMAZOLAM FRESENIUS KABI ONCOLOGY LIMITED (IN) 2025-08-21 US claimed
CN-119320567-B Asphalt solid phase composition for coating, modified asphalt coated natural graphite anode material, preparation thereof and lithium ion battery 五矿勘查开发有限公司 2025-03-07 CN claimed
EP-4504731-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF REMIMAZOLAM Fresenius Kabi Oncology Ltd (IN) 2025-02-12 EP claimed
CN-119320567-A Asphalt solid phase composition for coating, modified asphalt coated natural graphite anode material, preparation thereof and lithium ion battery 五矿勘查开发有限公司 2025-01-17 CN claimed
US-20240368063-A1 PREPARATION METHOD, INTERMEDIATE COMPOUNDS, AND SYNTHESIS METHOD FOR A CLASS OF ANTHRACENE-DERIVED TOXINS IN ORGANIC CHEMISTRY WUYAN PHARMACEUTICAL TECHNOLOGY (SHANGHAI) CO., LTD (CN) 2024-11-07 US claimed
CN-118638274-A Polyvinyl alcohol microsphere and preparation method and application thereof 湖南埃普特医疗器械有限公司 2024-09-13 CN claimed
CN-118359931-A Flow line master batch applicable to polycarbonate, preparation method and application 万华化学集团股份有限公司 2024-07-19 CN claimed
WO-2000029362-A1 1,4-DIARYL-2-FLUORO-1-BUTEN-3-OL COMPOUNDS AND THEIR USE IN THE PREPARATION OF 1,4-DIARYL-2-FLUORO-1,3-BUTADIENE AND 1,4-DIARYL-2-FLUORO-2-BUTENE COMPOUNDS AMERICAN CYANAMID COMPANY (US) 2000-05-25 WO claimed
EP-0955998-A2 MICROPARTICLES CONTAINING ACTIVE SUBSTANCES, AGENTS CONTAINING THE SAME, THEIR USE IN ULTRASOUND-CONTROLLED RELEASING OF ACTIVE SUBSTANCES AS WELL AS THE METHOD FOR THEIR PRODUCTION SCHERING AKTIENGESELLSCHAFT (DE) 1999-11-17 EP claimed
WO-1998020856-A2 MICROPARTICLES CONTAINING ACTIVE SUBSTANCES, AGENTS CONTAINING THE SAME, THEIR USE IN ULTRASOUND-CONTROLLED RELEASING OF ACTIVE SUBSTANCES AS WELL AS THE METHOD FOR THEIR PRODUCTION SCHERING AKTIENGESELLSCHAFT (DE) 1998-05-22 WO claimed
EP-0372009-A4 CONDUCTIVE POLYMER MATERIALS AND METHOD OF PRODUCING SAME 1990-09-05 EP claimed
EP-0372009-A1 CONDUCTIVE POLYMER MATERIALS AND METHOD OF PRODUCING SAME LOCKHEED CORPORATION (US) 1990-06-13 EP claimed
WO-1989007631-A1 CONDUCTIVE POLYMER MATERIALS AND METHOD OF PRODUCING SAME LOCKHEED CORPORATION (US) 1989-08-24 WO claimed
US-4851487-A Conductive polymer materials and method of producing same LOCKHEED CORPORATION (US) 1989-07-25 US claimed
EP-0225974-A2 Process for producing lactams with 8 to 15 carbon atoms from their corresponding oximes HÜLS AKTIENGESELLSCHAFT (DE) 1987-06-24 EP claimed
EP-0061761-A1 A method for preparing a mononucleotide-3'-phosphodiester-based substrate Baker Instruments Corporation (US) 1982-10-06 EP claimed
US-4115058-A BLEACHES, DETERGENTS FMC CORPORATION (US) 1978-09-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368063-A1 PREPARATION METHOD, INTERMEDIATE COMPOUNDS, AND SYNTHESIS METHOD FOR A CLASS OF ANTHRACENE-DERIVED TOXINS IN ORGANIC CHEMISTRY ANTXR2, AKR7A2, ACR HTR6 3877/4885ALDH1A1 1295/4885TDP1 3635/4885
US-12540140-B2 Process for the preparation of remimazolam SCN2B, HCN3, KCNH1 HTR6 1254/4885ALDH1A1 1255/4885TDP1 4519/4885
US-20250263414-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF REMIMAZOLAM CYP4F3, HRH4, HRH3 HTR6 518/4885ALDH1A1 873/4885TDP1 4717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.